RARE-11. EFFICACY AND SAFETY OF DABRAFENIB + TRAMETINIB IN PATIENTS WITH RECURRENT/REFRACTORY BRAF V600E–MUTATED LOW-GRADE GLIOMA (LGG)

BACKGROUND: Approximately 9%-18% of LGGs possess BRAF V600E mutations. Combined BRAF and MEK inhibition is efficacious in BRAF V600–mutated melanoma, lung cancer, and anaplastic thyroid cancer. Dabrafenib (BRAF inhibitor) + trametinib (MEK inhibitor) was evaluated as treatment for patients with recu...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Neuro Oncol
Auteurs principaux: Wen, Patrick, De Greve, Jacques, Mason, Warren, Hofheinz, Ralf-Dieter, Dietrich, Sascha, de Vos, Filip, van den Bent, Martin, Mookerjee, Bijoyesh, Boran, Aislyn, Burgess, Paul, Rangwala, Fatima, Gazzah, Anas
Format: Artigo
Langue:Inglês
Publié: Oxford University Press 2018
Sujets:
Abstracts
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6217698/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy148.988
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires